Nimbus Therapeutics has entered a collaboration and licensing agreement with Eli Lilly for potential therapeutics for metabolic diseases with a potential value of $496 million. The two companies will collaborate on the development of novel targeted therapies designed to activate a specific isoform of AMPK for the potential treatment of metabolic diseases. AMPK (AMP-activated protein kinase) is considered a high-value target in this indication due to its role in glucose, lipid metabolism, and inflammation. The companies will work to identify isoform-selective, small molecule activators of AMPK heterotrimers, believed to improve glucose and lipid homeostasis while mitigating safety concerns. Nimbus will apply its computational drug discovery engine to develop isoform-selective small molecule AMPK activators applicable in a broad range of metabolic diseases, leveraging Lilly
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!